• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Key drugs reduce fracture risk in osteoporosis

byKenan Celtik, MSandAimme Li, MD
September 9, 2014
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This systematic review demonstrated that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a significantly reduced risk of vertebral and nonvertebral fractures, compared to placebo.

2. The comparative effectiveness of the different pharmacological agents available to treat osteoporosis is unclear.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Osteoporosis is a disease characterized by reduced bone mineral density (BMD) and increased fracture risk. There are multiple pharmacological agents available used for the treatment of osteoporosis. This study included 294 systematic reviews and randomized controlled trials (RCTs) pertaining to drugs approved by the U.S. Federal Drug Administration (FDA) for primary osteoporosis, except for calcitonin and etidronate. This systematic review found high-strength evidence that in postmenopausal women with osteoporosis, bisphosphonates, denosumab and teriparatide were associated with a reduced risk of vertebral and nonvertebral fractures compared to placebo. There was limited evidence identified on the comparative effectiveness of the different pharmacological agents available to treat osteoporosis, although the study did suggest that all-resorptives were significantly more effective than vitamin D and calcium supplements in preventing fractures. The evidence on adverse effects was generally weak and many findings were inconsistent. It was also noted that alendronate, teriparatide and denosumab were associated with mild GI disturbances. Furthermore, the results suggested that cases of osteonecrosis of the jaw were associated with intravenous bisphosphonates, atypical subtrochanteric fracture was associated with longer duration of bisphosphonate treatment, and denosumab was associated with increased infection risk. The limitations of these analyses relate to differences in the study types, inclusion criteria, outcomes and lengths of follow-up.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-response Based Meta-analysis

In-Depth [systematic review]: This study was a follow-up to an AHRQ-funded study from 2011. It was initiated because of new data showing that zoledronic acid prevented all fractures at 24 and 36 months (RR 0.23 to 0.73) and two RCTs on denosumab, the newly introduced agent, reported reduced risk of hip, vertebral, nonvertebral and new clinical vertebral fractures (HR 0.31 to 0.8). Medical literature database searches yielded 55,086 titles from which 294 systematic reviews or RCTs on FDA-approved drugs for primary osteoporosis, except for calcitonin and etidronate, were eligible for inclusion. Bisphosphonates (alendronate, ibandronate, risedronate, and zoledronic acid), denosumab and teriparatide, compared to placebo, reduced the risk of vertebral fracture (RR 0.40 to 0.60) and nonvertebral fracture (RR 0.60 to 0.80) in postmenopausal women with osteoporosis. The number needed to treat over 1 to 3 years to prevent 1 vertebral fracture was 60 to 89 people and 50 to 67 people to prevent 1 hip fracture. Furthermore, there was limited evidence directly comparing bisphosphonates, denosumab or teriparatide in fracture prevention.

RELATED REPORTS

#VisualAbstract: Addition of denosumab to neoadjuvant paclitaxel does not improve complete response rate in breast cancer

Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures

Bisphosphonate use and risk of atypical femur fractures

More from this author: Rituximab not beneficial long-term in Sjorgen’s SyndromeHigh-energy shockwave therapy effective in treating shoulder calcific tendinitisTenofovir prophylaxis linked with reduced risk of herpes simplex 2

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: bisphosphonatesdenosumabosteoporosisteriparatide
Previous Post

Intermittent montelukast (singulair) fails to reduce medical visits in children with wheezing [WAIT trial]

Next Post

Updated guidelines for management of sickle cell disease released

RelatedReports

#VisualAbstract: Addition of denosumab to neoadjuvant paclitaxel does not improve complete response rate in breast cancer
StudyGraphics

#VisualAbstract: Addition of denosumab to neoadjuvant paclitaxel does not improve complete response rate in breast cancer

August 9, 2022
Eczema more prevalent among older adults than previously thought
Chronic Disease

Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures

January 27, 2021
Bisphosphonate use and risk of atypical femur fractures
Chronic Disease

Bisphosphonate use and risk of atypical femur fractures

August 26, 2020
Vitamin D supplementation amongst post-menopausal women did not improve functional outcomes
Chronic Disease

Delayed denosumab doses associated with increased the risk of vertebral fractures

July 30, 2020
Next Post
Updated guidelines for management of sickle cell disease released

Updated guidelines for management of sickle cell disease released

Cost-related medication nonadherence associated with increased ED utilization

Dementia patients frequently on medications with minimal benefit

No obesity paradox found between BMI, stroke, and death

Conclusions can change following reanalysis of randomized clinical trial data

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options